PlasmOnCo was founded at the unique intersection of cold atmospheric plasma physics and advanced bioengineering. Our pioneering research revealed how precisely tuned plasma dynamics could program biological responses within hydrogel matrices, offering unprecedented control over localized therapeutic delivery.
This fundamental discovery laid the groundwork for a new class of bio-interactive materials, designed specifically to overcome the systemic limitations of traditional chemotherapy and enhance treatment efficacy for solid tumors.
Advancing Precision in Localized Cancer Therapeutics
We are dedicated to creating measurable societal value by translating complex physics into clinical solutions. Our engineered oncology scaffolds aim to deliver high-precision, localized treatment options, minimizing systemic toxicity and maximizing therapeutic impact where it matters most.
Pioneers in Bioengineering & Plasma Medicine
Our leadership team brings together deep expertise across plasma physics, biomaterial synthesis, and translational oncology, united by a shared vision to transform cancer treatment.
Adrià Barceló
Dr. Cristina Canal
Dr. Cédric Labay
CEO. Materials Engineer with extensive experience in biomaterials & plasma medicine for cancer therapies, complemented by strong training in regulatory affairs, IP strategy, business development & technology transfer.
CSO & Full Professor in the Dept. of Materials Science Engineering at UPC. Head of the PlasmaMED Lab research group, integrated in the Institute for Research and Innovation in Health (IRIS). She specialized in cold plasma functionalization for biomedical applications.
CTO. With a PhD. Thesis & over 10-years research expertise in plasma technology for biomedical applications, he shifted towards tech transfer, valorization strategies, network building & business development.
• Support & Grants
Our translational milestones and plasma-hydrogel engineering are backed by competitive public research grants, deep-tech development programs, and leading clinical innovation networks.
Deep-Tech Accelerators
Competitive Grants
Institutional Backing
Selected for elite biotechnology acceleration cohorts that provide strategic mentoring, laboratory infrastructure, and regulatory guidance for translational oncology ventures.
Supported by competitive public science grants and tech-transfer funding dedicated to advancing cold atmospheric plasma applications in targeted drug delivery for biomedical applications.
Partnered with premier bio-engineering centers and oncology research groups to validate therapeutic efficacy across rigorous pre-clinical testing protocols.
Join us in advancing precision oncology. We welcome inquiries from investors, researchers, and pharmaceutical partners.